Business Context and Reporting Period
Company: RXi Pharmaceuticals Corporation (Note: Metadata lists "Phio Pharmaceuticals Corp.", but the filing text identifies the registrant as RXi Pharmaceuticals Corporation).
Filing Type: Form 8-K (Current Report).
Reporting Period: Quarter ended June 30, 2016.
Report Date: August 11, 2016.
Context: The company filed this report to announce its results of operations for the second quarter of 2016. The detailed financial data is contained in a press release attached as Exhibit 99.1, which is not incorporated by reference into this filing.
Key Financial Metrics
The provided text is a cover sheet for the Form 8-K and does not contain specific numerical data regarding revenue, profit, cash flow, margins, debt, or liquidity.
Status: The filing text does not provide a clear value for any financial metric. Investors must refer to the attached Exhibit 99.1 (Press Release) for these figures.
Material Changes
The filing text does not disclose specific material changes versus the prior comparable period. It only confirms that results for the quarter ended June 30, 2016, were reported.
Guidance, Outlook, and Risks
Management Commentary: The text confirms the release of Q2 2016 results but does not include specific commentary, guidance, or outlook statements within the 8-K body.
Risks and Contingencies: No specific risks or contingencies are detailed in this excerpt. The filing includes a standard disclaimer that the information in Item 2.02 and Exhibit 99.1 is not treated as "filed" under Section 18 of the Exchange Act and will not be incorporated by reference unless expressly stated.
Investor Verification Checklist
- Verify the correct registrant name: The filing is for RXi Pharmaceuticals Corporation, not Phio Pharmaceuticals Corp.
- Locate and review Exhibit 99.1 (Press Release dated August 11, 2016) to obtain actual revenue, net loss, and cash position figures.
- Confirm if the press release contains updated clinical trial timelines or regulatory milestones, as these are typical for biopharmaceutical 8-Ks.
- Note that the financial data in the press release is not legally "filed" with the SEC in this specific document context.